Wyeth, Orchid Reach Deal In Effexor Patent Fight

Law360 (April 15, 2011, 1:35 PM EDT) -- Wyeth LLC on Thursday struck a licensing deal with generics maker Orchid Chemicals & Pharmaceuticals Ltd. over Effexor XR, resolving a patent dispute in New Jersey over the blockbuster antidepressant and anti-anxiety drug.

Under the settlement, Orchid agreed not to manufacture venlafaxine HCl extended-release capsules — the active ingredient in the drug — until the expiration of three relevant patents, except as permitted by a confidential licensing agreement.

Wyeth and Orchid submitted the deal to Judge Freda L. Wolfson of the U.S. District Court for the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.